Prescribing complexity of oral hypoglycemic fixed-dose combinations in India: development and application of a novel complexity scoring tool

Sophia B. Modi; Sunilkumar G.

doi:10.18203/2319-2003.ijbcp20260057

Authors

Sophia B. Modi Department of Pharmacology, Government Medical College, Thiruvananthapuram, Kerala, India https://orcid.org/0000-0002-9921-6631
Sunilkumar G. Department of Pharmacology, Government Medical College, Idukki, Kerala, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20260057

Keywords:

Fixed-dose combinations, Oral hypoglycemic agents, Prescribing complexity, Rational drug use, India

Abstract

Background: Fixed-dose combinations (FDCs) of oral hypoglycemic agents are extensively used in India for simplifying type 2 diabetes mellitus (T2DM) treatment and improving adherence. There are long-standing concerns regarding irrational FDCs, limited dose flexibility, and weak alignment with clinical guidelines. Currently, no structured framework exists to assess the prescribing complexity of these FDCs. Objectives of the study were to characterize oral hypoglycemic agent FDCs approved and marketed in India and to develop and apply a novel prescribing complexity score for oral hypoglycemic fixed-dose combinations (PCS-OHA-FDC).

Methods: A secondary analysis of oral hypoglycemic agent FDCs approved by the Central Drugs Standard Control Organization and listed in standard drug information sources was conducted. Each FDC was evaluated across four domains: number of active pharmaceutical ingredients, therapeutic duplication, dose flexibility, and guideline concordance. Domain scores were summed to derive an overall prescribing complexity score and to classify FDCs as low, moderate, or high complexity.

Results: 57 OHA FDCs were included in the analysis. Two-drug FDCs constituted the majority (40/57; 70.2%), while there were 17 three-drug FDCs (29.8%). No FDC demonstrated direct therapeutic duplication. Limited dose flexibility (7/57; 12.3%) and conditional or absent guideline support (40/57; 70.17%) was common. Using the prescribing complexity score for OHA-FDCs (PCS-OHA-FDC), most formulations were classified as low complexity (42/57; 73.68%), with the remainder showing moderate complexity (15/57; 26.31%). No FDC met criteria for high prescribing complexity.

Conclusions: The PCS-OHA-FDC offers a practical tool to quantify prescribing complexity and highlights important gaps between market availability and guideline-based diabetes care in India.

Metrics

Metrics Loading ...

References

Bell DSH. Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab. 2013;15(4):291-300. DOI: https://doi.org/10.1111/dom.12015

Kalra S, Das AK, Priya G, Ghosh S, Mehrotra RN, Das S, et al. Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel. J Family Med Prim Care. 2020;9(11):5450-7. DOI: https://doi.org/10.4103/jfmpc.jfmpc_843_20

FOUNDATION OR. orfonline.org. Decoding the ban on irrational fixed-dose combination drugs in India. Available at: https://www.orfonline.org/research/ decoding-the-ban-on-irrational-fixed-dose-combination-drugs-in-india. Accessed on 01 November 2025.

Schmidt SJ, Wurmbach VS, Lampert A, Bernard S, Haefeli WE, Seidling HM, et al. Individual factors increasing complexity of drug treatment—a narrative review. Eur J Clin Pharmacol. 2020;76(6):745-54. DOI: https://doi.org/10.1007/s00228-019-02818-7

Al Haqimy Mohammad Yunus MA, Akkawi ME, Fata Nahas AR. Investigating the association between medication regimen complexity, medication adherence and treatment satisfaction among Malaysian older adult patients: a cross-sectional study. BMC Geriatr. 2024;24:447. DOI: https://doi.org/10.1186/s12877-024-05016-y

Central Drugs Standard Control Organization. Available at: https://cdsco.gov.in/opencms/ opencms/en/. Accessed on 01 November 2025.

FDC New Drugs Marketing. Available at: https ://cdsco.gov.in/opencms/opencms/en/Approval_new/FDC-New-Drugs-Marketing/. Accessed on 01 November 2025.

Drug Website, Directory & Medical Information. CIMS India. Available at: https://www.mims.com /india. Accessed on 01 November 2025.

ICMR_GuidelinesType2diabetes2018_0. ICMR. 2018. Available at: https://www.icmr.gov.in/ icmrobject/custom_data/pdf/resource-guidelines /ICMR_GuidelinesType2diabetes2018_0.pdf. Accessed on 01 November 2025.

RSSDI Guidelines & Position Statements. RSSDI. Available at: https://www.rssdi.in/newwebsite/page .php?id=114. Accessed on 01 November 2025.

American Diabetes Association Professional Practice Committee for Diabetes. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2025;49:S183-215.

Bhaskarabhatla A, Chatterjee C. The role of physicians in prescribing irrational fixed-dose combination medicines in India. Soc Sci Med. 2017;174:179-87. DOI: https://doi.org/10.1016/j.socscimed.2016.12.022